An Increased Level of Aryl Hydrocarbon Receptor in Patients with Pancreatic Cancer
Middle East Journal of Digestive Diseases · 04.10.2018 · 11 (1) · 38-44
DOI: 10.15171/mejdd.2018.126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Middle East Journal of Digestive Diseases, online erschienen am 04.10.2018. Verfasst von Sahar Masoudi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND Aryl-carbon receptor (AhR), a ligand-activated transcription factor, is best known for its ability to mediate the effects of environmental toxins such as 2,3,7,8-tetrachlorodibenzo-p-dioxin. AhR is expressed in several tumor cells and regulates the expression of genes in the signal transduction pathways. In this study, we examined the soluble levels of AhR in patients with pancreatic cancer. METHODS 123 samples, including 59 (48%) samples of pancreatic ductal adenocarcinoma based on histological evidence and 64 (52%) healthy control samples, were evaluated to determine plasma levels of AhR by Enzyme-linked immunoassay. RESULTS The median of AhR among patients was 0.280 ng/mL, which differed considerably from 0.07 ng/mL in the control group (p < 0.001). Significant differences of the AhR were observed between the plasma samples of the patients compared with the healthy group, with respect to male sex (p < 0.001), age groups (p = 0.001), diabetic status (p < 0.001), body mass index (BMI) categories (p = 0.035), and constantly smokers (p < 0.001). We also observed significant differences between the level of AhR expression between men and women (p = 0.01) and ever to never smokers (p = 0.009) in the case group. In addition, the age of 65 and a BMI of 25 or less were significant factors in plasma AhR levels ([1.61 95%CI 1.08-2.38] and [1.84 95%CI 1.22-2.77], respectively). CONCLUSION The results of this study can add diagnostic information to pancreatic cancer involving AhR and the potential efficacy of this receptor in therapeutic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Zitieren
APA
Masoudi, S., Hassanzadeh Nemati, A., Fazli, H. R., Beygi, S., Moradzadeh, M., Pourshams, A., & Mohamadkhani, A. (2018). An Increased Level of Aryl Hydrocarbon Receptor in Patients with Pancreatic Cancer. Middle East Journal of Digestive Diseases, 11(1), 38-44. https://doi.org/10.15171/mejdd.2018.126
Vancouver
Masoudi S, Hassanzadeh Nemati A, Fazli HR, Beygi S, Moradzadeh M, Pourshams A, et al. An Increased Level of Aryl Hydrocarbon Receptor in Patients with Pancreatic Cancer. Middle East Journal of Digestive Diseases. 2018;11(1):38-44. doi:10.15171/mejdd.2018.126
BibTeX
@article{Masoudi2018,
author = {Masoudi, Sahar and Hassanzadeh Nemati, Amin and Fazli, Hamid Reza and Beygi, Samira and Moradzadeh, Maliheh and Pourshams, Akram and Mohamadkhani, Ashraf},
title = {An Increased Level of Aryl Hydrocarbon Receptor in Patients with Pancreatic Cancer},
journal = {Middle East Journal of Digestive Diseases},
year = {2018},
volume = {11},
number = {1},
pages = {38--44},
doi = {10.15171/mejdd.2018.126}
}
EUVIMED